Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Chill Brands appointed primary distribution partner by Relx International

(Sharecast News) - Chill Brands said on Monday that it has been appointed as primary distribution partner in the UK for Relx International, a "global leader" in the vaping sector. Under the terms of the agreement, Chill Brands will build a dedicated sales team to distribute Relx's UK-compliant pod system devices nationwide, with a primary focus on independent convenience stores, which it said was the "core strength" of the Chill Connect division.

"By combining Relx's global expertise with Chill Connect's specialist route-to-market capabilities, Chill Brands' board believes that this partnership is positioned to capture meaningful market share in the UK vape category," it said.

The first Relx stocks to be supplied by Chill Brands are expected to arrive in the UK this month, with the working capital required to execute the agreement to be financed through the existing inventory financing facility announced in December 2023.

Chief executive Callum Sommerton said: "This distribution agreement between Chill Brands and Relx International marks a significant milestone in our growth journey. Relx is a leading global vape company, and as their primary UK distribution partner we gain the opportunity to introduce a proven, science-led product range into one of the fastest-evolving vape markets in the world.

"With our established capabilities in convenience store distribution, Chill Brands is positioned to drive uptake of this product range."

Sommerton said the deal is expected to deliver a "material" increase in revenues for Chill Brands as the company expands Relx's market share in the UK through its dedicated sales team and specialist route-to-market capabilities.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.